

Lydia Warburton

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2115723/lydia-warburton-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

209
citations

6
h-index

13
g-index

13
ext. papers

282
ext. citations

5.7
avg. IF

2.89
L-index

#	Paper	IF	Citations
13	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
12	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2021 ,	8.7	2
11	Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. <i>Journal of Physical Education and Sports Management</i> , 2021 , 7,	2.8	2
10	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021 , 28, 100405	2	0
9	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 5926-5933	12.9	21
8	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020 , 12,	6.6	1
7	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond Mutant Detection. <i>Cancers</i> , 2020 , 12,	6.6	5
6	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer-a case report. <i>BMC Cancer</i> , 2019 , 19, 1109	4.8	7
5	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 26-30	1.9	10
4	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. <i>Molecular Oncology</i> , 2019 , 13, 171-184	7.9	27
3	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018 , 18, 726	4.8	50
2	Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of fimmunomodulatoryfenterocolitis. <i>Pathology</i> , 2018 , 50, 466-469 ^{1.6}	1.6	0
1	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <i>Cancer Letters</i> , 2017 , 404, 62-69	9.9	83